Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback